Thats all true except that CDX talked up the relationship and...

Thats all true except that CDX talked up the relationship and their approach to the launch in the last 4C.
Personally I think they over cooked it as in the same release they mentioned a return to profitability late 2022 so it was obviously never going to have a big impact on the bottom line.They would have been better to not show case it as their first new product release if they were not going to follow up with a bit of a PR push on release. For me, its always been abut 2022 and are confident well see better consolidated movement in the share price as we talk about that.